Epitope cleavage by Leishmania endopeptidase(s) limits the efficiency of the exogenous pathway of major histocompatibility complex class I-associated antigen presentation.
The activation of CD8+ T cell responses is commonplace during infection with a number of nonviral pathogens. Consequently, there has been much interest in the pathways of presentation of such exogenous antigens for major histocompatibility complex class I-restricted recognition. We had previously shown that Leishmania promastigotes transfected with the ovalbumin (OVA) gene could efficiently target OVA to the parasitophorous vacuole (PV), with subsequent recognition by class II-restricted T cells. We now report the results of studies aimed at evaluating the PV as a route of entry into the exogenous class I pathway. Bone marrow-derived macrophages can present soluble OVA (albeit at high concentrations) to the OVA(257-264)-specific T cell hybridoma 13.13. In contrast, infection with OVA-transfected Leishmania promastigotes failed to result in the stimulation of this hybridoma. This appeared unrelated to variables such as antigen concentration, parasite survival, and macrophage activation status. These results prompted an analysis of the effects of promastigotes on class I peptide binding using RMA-S cells and OVA(257-264). Our data indicate that the major surface protease of Leishmania, gp63, inhibits this interaction by virtue of its endopeptidase activity against the OVA(257-264) peptide. The data suggest that this activity, if maintained within the PV, would result in loss of the OVA(257-264) epitope. Although we can therefore draw no conclusions from these studies regarding the efficiency of the PV as a site of entry of antigen into the exogenous class I pathway, we have identified a further means by which parasites may manipulate the immune repertoire of their host.
Garcia
M R
MR
Department of Medical Parasitology, London School of Hygiene and Tropical Medicine, GB.
Graham
S
S
Harris
R A
RA
Beverley
S M
SM
Kaye
P M
PM
D000818:Animals; D017951:Antigen Presentation; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D006224:Cricetinae; D010450:Endopeptidases / Q000032:analysis* / Q000502:physiology*; D011992:Endosomes / Q000276:immunology / Q000378:metabolism; D000939:Epitopes / Q000276:immunology / Q000378:metabolism*; D006183:H-2 Antigens / Q000276:immunology / Q000378:metabolism*; D006863:Hydrogen-Ion Concentration; D007893:Leishmania donovani / Q000201:enzymology* / Q000254:growth & development / Q000276:immunology; D007898:Leishmaniasis, Visceral / Q000201:enzymology / Q000276:immunology; D008213:Lymphocyte Activation; D008647:Mesocricetus; D008666:Metalloendopeptidases / Q000502:physiology; D051379:Mice; D008810:Mice, Inbred C57BL; D010047:Ovalbumin / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D015800:Protozoan Proteins / Q000378:metabolism / Q000502:physiology; D013347:Subcellular Fractions / Q000276:immunology; D014162:Transfection / Q000276:immunology
D000939:Epitopes; D006183:H-2 Antigens; C032876:H-2Kb protein, mouse; D015800:Protozoan Proteins; D010047:Ovalbumin; D010450:Endopeptidases; D008666:Metalloendopeptidases; C055146:glycoprotein gp63, Leishmania